NASDAQ · STOCK
CVS Health
$104.17
52W $58.50 – $106.15
57/100
$131.18B
45.5
0.59
Price History (6M)
Executive Summary
5 analysts weighed in with 60% agreement on a bullish lean. Growth Analyst: 4 consecutive earnings beats -- consistent execution. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
- Daily trend: uptrend.
- Weekly trend: uptrend.
- Daily and weekly trends are both bullish — multi-timeframe alignment, highest confidence.
- Higher Highs / Higher Lows structure confirms bullish price action.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- MACD histogram is negative (-0.390) — bearish momentum.
- Risk/reward is unfavorable: 3.7% downside vs 0.4% upside.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
57/100
Agreement
57%
Analysts
7
Conviction
Contested
Growth Analyst
bullish
82
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ 4 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
57
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
58.2
Neutral
MACD Histogram
-0.390
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$100.27
Resistance
$104.62
Bollinger %B
0.72
Inside Bands
Price vs Moving Averages
EMA 9
$103.51
Above
EMA 21
$101.60
Above
EMA 50
$96.04
Above
EMA 200
$83.34
Above
Fundamental Analysis
Valuation
50
Growth
60
Profitability
9
Financial Health
43
Valuation
P/E Ratio
45.5×
P/B Ratio
1.34×
PEG Ratio
—
Dividend Yield
2.59%
52W High
$106.15
52W Low
$58.50
Quality & Growth
ROE
387.0%
ROA
115.0%
Gross Margin
1387.0%
Operating Margin
158.0%
Revenue Growth YoY
+764.0%
Debt / Equity
0.86
AI Fundamental Assessment
P/E ratio of 45.5 (rich relative to a 15-40x range); Price-to-book of 1.3x; Revenue growth (YoY) of 7.6%; EPS growth (YoY) of -46.0%; Return on equity of 3.9%; Return on assets of 1.1%; Net margin of 0.7%; Gross margin of 13.9%; Current ratio of 0.84 (tight short-term liquidity); Debt-to-equity of 0.86; Most recent quarter beat estimates by 15.8%; 4 consecutive earnings beats; EPS growth accelerating (-31.9% -> +135.8% QoQ); Analyst estimates rising over recent quarters
Key Risks
- MACD histogram is negative (-0.390) — bearish momentum.
- Risk/reward is unfavorable: 3.7% downside vs 0.4% upside.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full CVS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile